Login / Signup

Effect of ET-A blockade on portal pressure and hepatic arterial perfusion in patients with cirrhosis: A proof of concept study.

Alexander ZipprichFleur GittingerMatthias WinklerMatthias M DollingerCristina Ripoll
Published in: Liver international : official journal of the International Association for the Study of the Liver (2021)
Administration of a selective ET-A antagonist decreases the portal pressure in cirrhotic patients. This decrease was higher in CP B patients and the non-responders showed a higher increase in hepatic arterial flow. Selective ET-A antagonists might be a future treatment option in patients with portal hypertension.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • blood pressure
  • computed tomography
  • magnetic resonance
  • contrast enhanced